EUCTR2006-001761-42-LT进行中（未招募）1 期
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patient is at least 18 years of age.
- •Patient is scheduled to undergo open abdominal surgery or laparoscopically-assisted vaginal hysterectomy requiring overnight hospital stay (24-hour hospital stay after surgery).
- •Patient is scheduled to receive general anesthesia, including induction agents, narcotics, neuromuscular blocking agents, and maintenance with nitrous oxide (50 to 70%) with volatile anesthetic.
- •Patient is scheduled to receive postoperative opioids by IM or IV route, or by IV patient-controlled analgesia.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patient is expected to receive propofol for maintenance of anesthesia.
- •Placement of a nasogastric or oral gastric tube intra or postoperatively (patients should be excluded if these are routinely used for the type of surgery to be performed.)
- •Patient is expected to receive neuroaxial anesthesia/analgesia (patients should be excluded if neuroaxial anesthesia/analgesia is routinely used for the type of surgery to be performed.)
- •Please see Protocol for additional criteria.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)Postoperative Nausea and VomitingClassification code 10036238EUCTR2006-001761-42-ATMerck Sharp & Dohme GesmbH700
进行中（未招募）
不适用
A Randomized, Double-Blind, Active Comparator, Non-Inferiority Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects with Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel) - NAEUCTR2010-019001-42-BGTeva Pharmaceutical Works Private Limited Company300
进行中（未招募）
1 期
A study to evaluate the long-term safety and tolerability of SEP-363856 compared with an approved medicine in subjects with schizophrenia.MedDRA version: 20.0Level: LLTClassification code 10039632Term: Schizophrenia NOSSystem Organ Class: 100000004873SchizophreniaEUCTR2019-002259-40-ROSunovion Pharmaceuticals Inc.300
进行中（未招募）
1 期
Randomized, Blinded Trial to compare a Single Injection of Cingal® (Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide) with Cross-Linked Sodium Hyaluronate alone and with Triamcinolone Hexacetonide alone for Providing Symptomatic Relief of Osteoarthritis of the KneeOsteoarthritis of the KneeMedDRA version: 20.0Level: LLTClassification code 10031165Term: Osteoarthritis kneeSystem Organ Class: 100000004859EUCTR2017-000355-46-PLAnika Therapeutics, Inc.576
进行中（未招募）
1 期
A trial investigating the mechanism of action of NNC0109-0012 (anti-IL-20 mAb) through synovial biopsies in subjects with rheumatoid arthritis and an inadequate response to MethotrexateMedDRA version: 16.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2013-001492-20-PTovo Nordisk A/S42